Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo controlled, two-way cross-over study to explore the effects of 7 days of dosing with SYN115 20 mg p.o. bid or 60 mg p.o. bid on clinical and fMRI response to intravenous levodopa in patients with mild to moderate Parkinson's disease

Trial Profile

A randomized, double-blind, placebo controlled, two-way cross-over study to explore the effects of 7 days of dosing with SYN115 20 mg p.o. bid or 60 mg p.o. bid on clinical and fMRI response to intravenous levodopa in patients with mild to moderate Parkinson's disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Synosia Therapeutics
  • Most Recent Events

    • 13 Jun 2010 Perfusion MRI results presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
    • 14 Apr 2010 Perfusion MRI results presented at the 62nd Annual Meeting of the American Academy of Neurology.
    • 14 Apr 2010 Results presented at 62nd Annual Meeting of the American Academy of Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top